Introduction
The number of compounds approved for use as new drugs is very small compared to the number of drug candidates that progress from pre-clinical to clinical trials. The proportion was just 8% for central nervous system (CNS)-acting drugs during the period from 1991 to 2000 (Kola and Landis, 2004) , and also no greater during the period from 2000 to 2008 (Yagi and Ohkubo, 2010) . One of the major reasons for the high rate of discontinuation has been the unfavorable distribution of drugs into human brain. More than 98% of small molecules do not cross the blood-brain barrier (BBB) and thus do not provide pharmacologically active concentrations in brain (Pardridge, 2002) . It has been also reported that there are 7638 molecules in the Comprehensive Medicinal Chemistry database but only 387 (5.1%) of these molecules treat CNS diseases (Ghose et al., 1999) . Therefore, it's necessary to determine quantitative and accurate prediction of drug distribution in human brain during the pre-clinical stages. Brain drug distribution depends on permeability rate across the BBB regulated by a variety of transporters expressed in brain capillary endothelial cells. ATP-binding cassette (ABC) transporters P-gp/MDR1/mdr1a/ABCB1 and BCRP/ABCG2 are major gatekeepers for many drugs (Kusuhara and Sugiyama, 2009; Uchida et al., 2011b) . Therefore, it's important to quantitatively clarify the molecular functions of these transporters at the human BBB to predict drug distribution in the human brain.
Protein expression levels have been reported to correlate with activities of functional proteins (Dyer et al., 1997; Hoffmeyer et al., 2000; Fukumoto et al., 2002; Shirasaka et al., 2008; Langenfeld et al., 2009; Tachibana et al., 2010) . Hence, we anticipated that in-vivo functional activities of target transporters could be reconstructed based on their in-vitro activities by integrating these activities with the in-vivo/in-vitro differences in protein expression levels. We developed an absolute protein quantification method for transporters using LC-MS/MS, termed "quantitative targeted absolute proteomics (QTAP)" (Kamiie et al., 2008) . Using QTAP, we demonstrated in mouse model that in-vivo P-gp/mdr1a function at the BBB was reconstructed by integrating the protein expression levels of P-gp/mdr1a in the in-vivo brain capillaries with the transport function per P-gp/mdr1a molecule, which was determined using an in-vitro transport experiment and QTAP (Uchida et al., 2011a) . This demonstration opened a new field of pharmacoproteomics (PPx), which is an integrated scientific field of proteomics and pharmacokinetics/pharmacodynamics/toxicokinetics/toxicodynamics to quantitatively understand drug ADME, pharmacological effect and toxicity (Uchida et al., 2014) .
However, brain distributions of P-gp substrates, such as [ 18 F]altanserin and [ 11 C]GR205171, significantly differ between humans and rodents (Syvanen et al., 2009) .
Therefore, it's debatable whether the demonstration of in-vitro-to-in-vivo reconstruction in a mouse model alone is sufficiently valid to apply the theory to reconstruction of in-vivo P-gp function at the human BBB, although this reconstruction is theoretically applicable regardless of animal species. In contrast, the quantitative protein expression profile of BBB transporters in cynomolgus monkeys is quite similar to that in humans (e.g., only 1.29-fold difference from humans in P-gp protein levels) (Ito et al., 2011; Uchida et al., 2011b ).
It's also important to overcome species difference in brain drug distribution.
Brain-to-plasma concentration ratios (K p brain ) of P-gp substrate verapamil and PF-00905556 in monkey are significantly 10.8-and 12.2-fold greater than those in mouse and rat, respectively (Hendrikse et al., 1998; Kpakima et al., 2006; Syvanen et al., 2009) . Between monkey and rodents, the protein expression levels of P-gp/mdr1a at the BBB differ only by 3-4-fold (Kamiie et al., 2008; Ito et al., 2011; Hoshi et al., 2013) . Therefore, the remarkable species differences in K p brain cannot be completely explained by the differences in protein expression levels. It's necessary to consider the species differences not only in protein expression levels but also in other factors such as intrinsic transport activity and unbound
Materials and Methods
Chemicals: Buspirone hydrochloride, loperamide hydrochloride, and quinidine were purchased from Sigma Chemical Co. (St. Louis, MO). Diazepam, paclitaxel, and verapamil hydrochloride were purchased from Wako Pure Chemicals (Osaka, Japan). Indinavir sulfate was purchased from Toronto Research Chemicals Inc. (North York, Canada). P-gp peptides with >95% peptide purity were synthesized by Thermo Fisher Scientific (Sedanstrasse, Germany). All of the other chemicals were of reagent grade and were available commercially.
Animals:
Six male adult cynomolgus monkeys were used for the intravenous constant infusion study and the absolute quantification of P-gp protein expression in isolated brain microvessels. The animals were treated as follows: 1) aged 5 years (y) and 2 months (m) with a body weight (BW) of 3.6 kg was treated with indinavir; 2) aged 4 y 1 m with a BW of 2.6 kg was treated with quinidine; 3) aged 6 y 4 m with a BW of 5.4 kg was treated with loperamide; 4) aged 5 y 4 m with a BW of 3.4 kg was treated with paclitaxel; 5) aged 4 y 3 m with a BW of 3.15 kg was treated with diazepam; and 6) aged 4 y 1 m with a BW of 3.2 kg was treated with verapamil. The six cynomolgus monkeys received intravenous constant infusions of the test compounds after fasting overnight with free access to water at HAMRI, Co., Ltd. (Ibaragi, Japan), after which the right cerebrums were used to determine the compound concentrations in the cerebrums and the left cerebrums were used for the P-gp quantifications in the brain microvessels.
Another male adult cynomolgus monkey, aged 4 y 1 m with a BW of 3.3 kg, was used as a blank control for the intravenous constant infusion study. The control cynomolgus monkey underwent the same procedure as the six cynomolgus monkeys outlined above without compound administration at HAMRI, Co., Ltd. (Ibaragi, Japan). The plasma and cerebrum of the control cynomolgus monkey were used as blank samples for the concentration determinations of the six test compounds in the plasma and cerebrum, respectively. The cerebrum of the control animal was also used for the measurements of the unbound fractions in the cerebrum. 1.2 mg/kg doses. Loperamide and paclitaxel were intravenously infused for 3 h at dose rates of 0.20 and 0.94 mg/h/kg, respectively, without intravenous bolus injections. One cynomolgus monkey was used for each compound. Prior to administration and at 2, 2.5, and 3 h after administration, blood samples were collected using syringes containing EDTA-2K without anesthesia from the cephalic or saphenous vein on the opposite side of that used for administration. The blood samples were immediately centrifuged at 4°C and 3500 x g for 10 min to obtain plasma. The plasma samples were stored at -80°C prior to LC-MS/MS analyses.
Immediately after the blood sampling at 3 h, the cynomolgus monkeys were sacrificed by exsanguination under anesthesia with isoflurane inhalation or excessive anesthesia with pentobarbital without exsanguination, and the brains were immediately excised, divided into at 4°C and 960 x g for 10 min and subjected to LC-MS/MS analyses. Based on pharmacokinetic concepts, the brain-to-plasma concentration ratios (K p brain ) at 3 h were estimated by dividing the cerebral concentrations by the plasma concentrations.
Transcellular transport study across cynomolgus monkey P-gp-transfected LLC-PK1
and parental LLC-PK1 cell monolayers: Cynomolgus monkey P-gp-transfected LLC-PK1
and parental LLC-PK1 cells were prepared at Merck Research Laboratories (West Point, PA) (Sankaranarayanan et al., 2009 ). The transcellular transport study was carried out as described previously (Uchida et al., 2011a) For basal to apical transport, the short interval (10 min) between sampling times (10, 20, and 30 min after initiation) was selected to maintain the concentration in the donor compartment sufficiently higher than that in the acceptor compartment to prevent the underestimation of donor-to-acceptor transport. At each sampling time, 100 µL aliquots were taken from the apical side, the culture inserts (apical side) were transferred to new (vacant)
wells of a 24-well plate that had been prewarmed at 37°C, the buffer in the insert was completely removed, and 0.5 mL of fresh transport buffer with and without the test compounds (37°C) was added to the basal and apical sides, respectively, to maintain sink conditions. For apical to basal transport, 100 µL aliquots were taken from the basal side at each sampling time (30, 60, and 90 min), the culture inserts (apical side) were transferred to new (vacant) wells of a 24-well plate that had been prewarmed at 37°C, and 0.5 mL of fresh transport buffer (37°C) was added to the basal side to maintain sink conditions. One hundred microliters of acetonitrile containing buspirone (internal standard) was added to 100 µL of the collected samples, and the mixtures were then subjected to LC-MS/MS analyses to quantify the amounts of the test compounds that had been transported to the acceptor side.
The transported amounts (pmol/well) were plotted against the transport time (min), and then the transport rate (fmol/min/well) was obtained by the linear regression of three sampling time points. The flux ratio was obtained by dividing the transport rate in the basal-to-apical direction by that in the apical-to-basal direction. The flux ratio in the under the same conditions as those used in the transcellular transport study, and the cells were used for the experiments on the fourth day after seeding. The apical and basal sides were washed with ice-cold PBS(-) twice, and the cells were harvested from six inserts using 1 mL/insert of ice-cold PBS(-) by scraping and centrifuged at 4°C and 230 x g for 5 min. The cell pellets were dissolved with 400 μ L of TS buffer (10 mM Tris-HCl, 250 mM sucrose, pH 7.4) and suspended well using a 1.0 mL syringe with a 27G × 1/2" needle to obtain a whole-cell lysate.
Cynomolgus monkey brain microvessels were isolated from the left cerebrums that had been excised from the cynomolgus monkeys used for the in-vivo constant infusion study.
The microvessels were isolated by using a combination of dextran density gradient separation and size filtration (nylon mesh method). The isolation procedure was the same as that described in Ito et al. (2011) .
This article has not been copyedited and formatted. The final version may differ from this version. The protein expression levels of cynomolgus monkey P-gp in the whole-cell lysates of cynomolgus monkey P-gp-transfected LLC-PK1 cells and the whole-tissue lysates of the isolated cynomolgus monkey brain microvessels were determined by using the same procedure as that described in Ito et al. (2011) .
Determination of the unbound fractions in cynomolgus monkey plasma using the equilibrium dialysis method: Cynomolgus monkey plasma (KAC Co. Ltd., Kyoto, Japan)
samples were adjusted to pH 7.4 with saturated CO 2 prior to sample preparation. Five microliters of 50% acetonitrile-containing test compound (50 µM) was added to 495 µL of the plasma to obtain a 0.5 µM final concentration in the plasma. One-hundred-and-twenty microliters of PBS (pH 7.4) and 120 µL of plasma containing the compounds were placed in the dialysate and sample sides of the 96-well micro-equilibrium dialysis device (HTD 96b;
HTDialysis, Gales Ferry, CT), respectively, with HTD 96a/b Dialysis Membrane Strips (MWCO 12-14K; HTDialysis). The wells were sealed and rotated in a 10% CO 2 incubator at 37°C and 80 rpm with a multi-shaker (TOKYO RIKAKIKAI Co. Ltd., Tokyo, Japan). After a 6 h incubation, 5 µL of plasma and 50 µL of dialysate were collected from the sample and dialysate sides, respectively, and transferred to 96-well format polypropylene plates. Fifty microliters of control PBS and 5 µL of control plasma were added to the collected plasma and dialysate samples, respectively. One-hundred-and-fifty microliters of acetonitrile-containing buspirone (internal standard) was added (205 µL in total) and vortexed. The samples were centrifuged and filtrated at 4°C and 960 x g for 10 min and subjected to LC-MS/MS analyses.
The unbound fractions of the test compounds in the cynomolgus monkey plasma were calculated based on the ratio of the concentrations that was determined from the plasma and dialysate samples. ( )
According to the pH partition model reported in Friden et al. (2011) , f u,brain values that were more relevant to the in-vivo condition were calculated using the values of f u,brain determined using the homogenate method above (eq. 1) and the reported pKa values of the test compounds (see the legend for Table 3 ).
LC-MS/MS analyses of the compounds:
The sample analyses were automated by coupling a In-vivo P-gp function at the cynomolgus monkey BBB is defined as the K p brain ratio, which is the ratio of K p brain in P-gp knockout animals to that in wild-type animals. As previously described (Uchida et al., 2011a) , the K p brain ratio was reconstructed using the equation presented below (eq. 2) and the in-vitro P-gp efflux ratio and protein expression levels of P-gp in the cynomolgus monkey P-gp-transfected LLC-PK1 cell monolayer and isolated cynomolgus monkey brain microvessels.
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The K p brain in cynomolgus monkeys was reconstructed in eq. 3 using the reconstructed K p brain ratio (eq. 2) and the unbound fractions in the plasma (f u,plasma ) and brain (f u,brain ), which were measured using the homogenate method and the pH partition model.
Furthermore, the K p,uu,brain is defined as follows:
The K p,uu,brain in cynomolgus monkeys was reconstructed as the reciprocal of the reconstructed K p brain ratio in eq. 5, which was obtained using eq. 3 and eq. 4:
We were unable to determine the observed K p brain ratio in cynomolgus monkeys because we This article has not been copyedited and formatted. The final version may differ from this version. did not have a P-gp knockout cynomolgus monkey. However, the observed K p brain and K p,uu,brain can be determined via in-vivo experiments with wild-type cynomolgus monkeys and consist of the K p brain ratio, as described in eq. 3 and eq. 5. Therefore, the reconstructions of the K p brain and K p,uu,brain can be validated by comparing the reconstructed values with the observed values. The reconstruction of the K p brain ratio can also be evaluated based on the validation of the K p brain and K p,uu,brain reconstructions, leading to the validation of in-vitro-to-in-vivo reconstruction of P-gp function at the cynomolgus monkey BBB.
Quantitative evaluation of the effects of individual parameters on species differences in K p brain and K p,uu,brain between cynomolgus monkeys and mice: Using eq. 2 and eq. 3, the K p brain is described by four parameters, as follows:
where PL p-gp,vivo represents the protein expression levels of P-gp in isolated brain microvessels and TA int,p-gp represents the intrinsic transport activity per P-gp molecule, which is calculated as [(In-vitro P-gp efflux ratio) -1]/[P-gp protein expression levels in P-gp-transfected LLC-PK1 cells]. Therefore, the species differences in the K p brain between cynomolgus monkeys and mice are described as follows: 
+ =
Therefore, the species differences in the K p,uu,brain between cynomolgus monkeys and mice are described as follows: 
+ + =
In the present study, the contributions of individual parameters to the species differences in the K p brain and K p,uu,brain between cynomolgus monkeys and mice were described as the "Impact on K p,monkey /K p,mouse " and the "Impact on K p,uu,monkey /K p,uu,mouse ," respectively. To quantitatively evaluate the contributions of each parameter, the "Impact on K p,monkey /K p,mouse " and the "Impact on K p,uu,monkey /K p,uu,mouse " were calculated using the following equations: 
where the K p,monkey(mouse) consists of three cynomolgus monkey parameters and one mouse parameter. Briefly, the mouse data were used for either one of PL p-gp,vivo,monkey(mouse) , TA int,p-gp,monkey(mouse) , f u,plasma,monkey(mouse) , or f u,brain,monkey(mouse), which was a targeted parameter for the evaluation of contribution, and the cynomolgus monkey data were used for the other three parameters. In the same manner as the K p,monkey(mouse) , only one of the evaluated parameters was derived from the mouse data and the others were derived from the cynomolgus monkey data for the K p,uu,monkey(mouse) . For the cynomolgus monkey data, the This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Determination of the steady-state brain-to-plasma concentration ratios (K p brain ) of five P-gp substrates and one non-substrate in cynomolgus monkeys: Indinavir, quinidine, loperamide, paclitaxel, verapamil, and a non-substrate diazepam were administered to male adult cynomolgus monkeys by continuous intravenous infusion, and the K p brain values were determined at steady-state (3 h) plasma concentrations ( Table 1 ). The plasma concentrations of the six compounds at 3 h ranged from 0.0331 to 0.541 μ M, which were lower than the reported K m values for P-gp that were determined using the ATPase assay (Adachi et al., 2001 ). The K p brain values of the six compounds in cynomolgus monkeys varied by 15-fold (Table 1) .
Reconstruction of in-vivo P-gp function (K p brain ratio) at the cynomolgus monkey BBB:
The K p brain ratio is defined as the ratio of K p brain in P-gp knockout animals to that in wild-type animals and is a parameter that describes in-vivo P-gp function at the BBB. The reconstruction of the K p brain ratio from the in-vitro experiments has been previously demonstrated in mice (Uchida et al., 2011a) . To demonstrate the reconstruction theory in cynomolgus monkeys as well as mice, we reconstructed the K p brain ratios for the six model compounds based on the in-vitro transport activities and protein expression levels of cynomolgus monkey P-gp according to the theory that was previously demonstrated in mice (eq. 2) as follows:
In the transcellular transport experiments using cynomolgus monkey P-gp-transfected LLC-PK1 cell monolayers and the parental LLC-PK1 cell monolayers shown in Fig. 1 , the in-vitro P-gp efflux ratio (a parameter reflecting the P-gp-specific transport activities of the test compounds) was determined and was found to range from 0.984 (diazepam) to 8.00 (loperamide) for the six compounds investigated (Table 2) . The protein expression levels of cynomolgus monkey P-gp were determined using quantitative targeted absolute proteomics (QTAP). The levels were 2.31 fmol/μg protein of whole-cell lysate in cynomolgus monkey P-gp-transfected LLC-PK1 cell monolayers and ranged from 5.05 to 7.07 fmol/μg protein of whole-tissue lysate in the isolated brain microvessels among the 6 cynomolgus monkeys administered the 6 compounds respectively, including data taken from the literature (Ito et al., 2011) (Table 2) .
Using these data, the K p brain ratios for the six compounds were reconstructed using eq.
2. The reconstruction of the K p brain ratio for each compound was performed using P-gp protein expression levels in the cynomolgus monkey that had been administered the corresponding compound. The reconstructed K p brain ratios of the six compounds ranged from 0.951 (diazepam) to 16.3 (loperamide) ( Table 2) .
Reconstruction of the K p brain of the five P-gp substrates and one non-substrate in cynomolgus monkeys:
The K p brain values for the six compounds in cynomolgus monkeys were reconstructed using eq. 3 and the reconstructed K p brain ratios and the unbound fractions in cynomolgus monkey plasma and brain (Table 3 ). The unbound fractions in the brain were measured using the homogenate method, converted to values that were more relevant to the in-vivo condition in combination with the pH partition model, and used for the K p brain reconstructions. The reconstructed K p brain values were within a three-fold range of the observed values for all six compounds ( Fig. 2A) .
Reconstruction of the K p,uu,brain of the five P-gp substrates and one non-substrate in cynomolgus monkeys: Using eq. 5, the K p,uu,brain values for the six compounds in cynomolgus monkeys were reconstructed as the reciprocals of the reconstructed K p brain ratios (Table 4) . (Fig. 2B) .
Reconstruction of species differences in the K p brain and K p,uu,brain between cynomolgus monkeys and mice: To clarify the species differences in drug distribution in the brain, we cited the observed K p brain and K p,uu,brain values in mice reported in Uchida et al. (2011a) , and divided the observed values in cynomolgus monkeys by those in mice (Fig. 3) . The K p brain values indicated that the differences between species (observed K p,monkey /K p,mouse ) were within a 0.657-10.9-fold range for the six compounds, with loperamide displaying the greatest difference (10.9-fold), followed by verapamil (5.22-fold). The species differences in the K p,uu,brain values of each of the six compounds (Estimated in-vivo K p,uu,monkey /K p,uu,mouse ) were within a 0.510-2.44-fold range.
It is important to establish the theory to quantitatively predict and overcome the species differences in brain drug distribution. To elucidate whether the species differences in K p brain and K p,uu,brain values could be reconstructed from the in-vitro experimental data, we reconstructed the ratios of the cynomolgus monkey values to the mouse values using eq. 7 and 9 (reconstructed K p,monkey /K p,mouse and reconstructed K p,uu,monkey /K p,uu,mouse ) and then compared these ratios with the observed ratios (Fig. 3) . For both the K p brain and K p,uu,brain values, the reconstructed ratios were within a three-fold range of the observed ratios, although the reconstructed ratios for indinavir were 3.13-fold higher than the observed ratios. 22 differences in the K p brain by calculating the "Impact on K p,monkey /K p,mouse " using eq. 10 (Table   5 ). For loperamide, the species differences in f u,plasma and PL p-gp,vivo were estimated to contribute to the 3.37-and 2.68-fold higher K p,monkey than K p,mouse , respectively, which were greater contributions than those of TA int,p-gp (0.550) and f u,brain (1.33). For verapamil, the species differences in PL p-gp,vivo , f u,plasma , and f u,brain were estimated to contribute to the 2.38-, 1.92-and 1.77-fold higher K p,monkey than K p,mouse , respectively.
For all six compounds, the species differences in PL p-gp,vivo and TA int,p-gp were estimated to contribute to the 2.16-2.68-fold (except for diazepam) and 0.550-1.22-fold species differences both in the K p brain and K p,uu,brain , respectively (Table 5 ). The species differences in f u,plasma and f u,brain only affected the K p brain , not the K p,uu,brain , and were estimated to contribute to the species differences in the K p brain of 0.369-11.1-fold and 0.313-1.87-fold, respectively, for the six compounds. 
Discussion
The present study is the first to experimentally demonstrate that the K p brain values of P-gp substrates and non-substrate can be reconstructed in non-human primate cynomolgus monkeys, an animal that is similar to humans, by integrating in-vitro P-gp transport activity, P-gp protein expression levels, and the unbound fractions in plasma and brain based on eq. 2 and eq. 3. This study is also the first to experimentally demonstrate that the K p,uu,brain values can be reconstructed by integrating in-vitro P-gp transport activity and P-gp protein expression levels based on eq. 2 and eq. 5.
In-vivo P-gp transport function at the BBB is defined as the K p brain ratio, which is the ratio of K p brain value in P-gp knockout animals to that in wild-type animals. Because a P-gp knockout monkey does not exist, we were unable to determine the observed value of K p brain ratio in monkeys, thereby making it impossible to directly validate the in-vitro-to-in-vivo reconstruction of K p brain ratio in monkeys. Eq. 3 indicates that the accuracy of reconstruction of K p brain value is directly influenced by that of K p brain ratio. Therefore, the successful reconstruction of K p brain value in this study has indirectly demonstrated that the K p brain ratio can also be precisely reconstructed from in-vitro P-gp transport activity and P-gp protein expression levels in monkeys. P-gp protein expression levels in brain microvessels only differ by 1.29-fold from those in humans (Ito et al., 2011; Uchida et al., 2011b) , and a good agreement between monkey P-gp and human P-gp has been also reported in the in-vitro transport activities for a variety of substrates (Takeuchi et al., 2006) . Therefore, the present demonstration of reconstruction theory suggests that our established pharmacoproteomics (PPx)-based reconstruction would be useful in clarifying in-vivo P-gp function at the human BBB.
Significant species differences in K p brain values were observed between monkeys and mice, with a maximum difference of 10.9-fold among six compounds (Fig. 3) in-vitro P-gp-transfected cells for predictions of in-vivo P-gp functions at the BBB and drug distribution in brain (Adachi et al., 2001; Feng et al., 2008) . However, it is challenging to make accurate predictions based on in-vitro experiments because the extent to which the transport functions and protein expression levels of P-gp differ between in-vivo BBB and in-vitro transfected cells is unclear. In this study, using monkeys that are similar to humans in terms of drug distribution in brain, we demonstrated that the K p brain and K p,uu,brain values can be predicted with ± three-fold accuracy from in-vitro experiments based on the in-vitro/in-vivo differences in protein expression levels of P-gp (Fig. 2) . Furthermore, we demonstrated that the species differences in K p brain and K p,uu,brain values can also be predicted from in-vitro studies with ± three-fold accuracy (Fig. 3) . Therefore, our established PPx-based reconstruction overcomes the species differences in drug distribution in brain and provides a useful method to rationally predict drug distribution in human brain from in-vitro experiments.
One of the advantages of K p brain and K p,uu,brain reconstructions based on several factors is that the contributions of individual factors can be quantitatively evaluated for changes in K p brain and K p,uu,brain values. As shown in Fig. 3 , remarkable species differences in K p brain values were observed for loperamide and verapamil between monkeys and mice. Table   5 summarizes the contributions of four factors (BBB P-gp protein expression levels (PL p-gp,vivo ), intrinsic transport activity per P-gp molecule (TA int,p-gp ), f u,plasma , and f u,brain ) to the species differences in K p brain and K p,uu,brain values of six compounds. For loperamide, the species differences in f u,plasma and PL p-gp,vivo were 3.37-and 2.79-fold, respectively, and contributed to 3.37-and 2.68-fold species differences in K p brain values, respectively. Smaller contributions were observed for the other two factors. These results suggest that major causes of the species differences in K p brain values of loperamide are differences in f u,plasma and PL p-gp,vivo between monkeys and mice. For verapamil, 2.71-, 1.92-, and 1.77-fold species differences in PL p-gp,vivo , f u,plasma , and f u,brain were observed, respectively, and these differences contributed to 2.38-, 1.92-, and 1.77-fold greater K p brain values in monkeys than in mice, respectively. These data suggest that the 5.22-fold greater observed K p brain values for verapamil in monkeys are caused by the species differences in these three factors.
Among the four factors, the species differences in f u,plasma showed the largest variation among six compounds, ranging from 0.369-(quinidine) to 11.1-fold (indinavir) differences between monkeys and mice ( Table 5 ). The "Impact on K p,monkey /K p,mouse " of f u,plasma also varied from 0.369 (quinidine) to 11.1 (indinavir), which was the largest variation among the four factors, suggesting that f u,plasma most significantly contributes to species variations in K p brain values. Several studies using a variety of compounds have indicated that there are the remarkable species differences in f u,plasma but no large differences in f u,brain (Fuse et al., 1998; Kratochwil et al., 2004; Di et al., 2011) . Table 5 shows that f u,brain did not affect the species differences in K p brain values of six compounds to as great an extent as f u,plasma . Therefore, unlike f u,plasma , f u,brain would not contribute substantially to species variations in K p brain values.
The K p,uu,brain value is independent of f u,plasma and f u,brain values, as shown in eq. 5 and Table 5 , and consequently species differences in K p,uu,brain values were smaller than those in K p brain values (Fig. 3) . As shown in eq. 2 and eq. 5, the K p,uu,brain value is affected only by PL p-gp,vivo and TA int,p-gp . PL p-gp,vivo differed by 2.00-to 2.79-fold between monkeys and mice, and TA int,p-gp did not differ so much (Table 5) . As a result, the "Impact on K p,uu,monkey /K p,uu,mouse " of PL p-gp,vivo ranged from 2.16-to 2.68-fold (with the exception of diazepam, which is not a P-gp substrate) and was greater than that of TA int,p-gp (Table 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. These data suggest that the PL p-gp,vivo is a major cause of the species differences in K p,uu,brain values. The species differences in P-gp protein expression levels at the BBB are two-to three-fold between humans and rodents, as is the case for monkeys and mice (Kamiie et al., 2008; Ito et al., 2011; Uchida et al., 2011b; Hoshi et al., 2013) . Therefore, the differences in the K p,uu,brain values of P-gp substrates between humans and rodents could typically range from approximately two-to three-fold, in accordance with the differences in protein expression levels. From this consideration, it is suggested that the K p,uu,brain values of P-gp substrates differ between humans and rodents but do not remarkably differ when compared to the species differences in K p brain values. Therefore, the measurement of K p,uu,brain value in rodents during drug development would be useful in understanding drug distribution in human brain.
The reconstructed brain distributions of six compounds in monkeys were within a three-fold range of the observed distributions but were not completely identical (Fig. 2) . One possible explanation is that the f u,brain used for the reconstruction was not identical to that in-vivo. Brain slice method can provide f u,brain values that are more relevant to in-vivo condition (Kakee et al., 1996; Ooie et al., 1997; Friden et al., 2007) . However, frozen monkey brains were used in this study to mimic the way of in-vitro-to-in-vivo reconstruction in humans, for which the brain is usually obtained in a frozen state. In frozen brain, the cells may be partially ruptured, and the f u,brain may not be accurately determined using the brain slice method. Therefore, we used the homogenate method with a pH partition model, which results in an f u,brain value that is more relevant to in-vivo condition than that obtained using the homogenate method alone (Friden et al., 2011) . However, this method does not take into account the involvement of active transport on the cell membrane of brain parenchyma, resulting in the possibility that the determined f u,brain differs from the true in-vivo value.
Another possible explanation is that only one monkey was studied for each compound to In conclusion, using cynomolgus monkeys as a robust human model, this study experimentally demonstrated that the K p brain and K p,uu,brain values of P-gp substrates and non-substrate can be reconstructed by integrating in-vitro P-gp transport activity, P-gp protein expression levels, and the unbound fractions in plasma and brain based on BBB PPx. These results also demonstrate that in-vivo P-gp transport function at the BBB can be reconstructed based on in-vitro P-gp transport activity and P-gp protein expression levels. These demonstrations illustrate the value of our established PPx-based reconstruction model for clarifying in-vivo function at the human BBB and predicting brain drug distribution in humans. Because not only P-gp but also BCRP at the BBB limit brain distributions of a number of drugs, further study would be needed in future to demonstrate that in-vivo function of BCRP can be reconstructed from in-vitro for the prediction of brain distribution for more drugs.
This article has not been copyedited and formatted. The final version may differ from this version. The cynomolgus monkey data were taken from Tables 1, 3 , and 4 and then divided by the mouse data cited in Uchida et al. (2011a) . The solid line passing through the origin represents the line of identity, and the broken lines represent three-fold differences. 1, indinavir; 2, quinidine; 3, loperamide; 4, paclitaxel; 5, diazepam; and 6, verapamil. This article has not been copyedited and formatted. The final version may differ from this version. Based on the results shown in Fig. 1 , the apical-to-basal (A to B) transport rate, the basal-to-apical (B to A) transport rate, the flux ratio, and the in-vitro P-gp efflux ratio across LLC-PK1/cynomolgus monkey P-gp-transfected LLC-PK1 cell monolayers were calculated as described in the Materials and Methods section. For the quantifications of P-gp expression, cynomolgus monkey P-gp-transfected LLC-PK1 cells were cultured under the same conditions that were used for the transcellular transport experiments, and the expression levels in the transfected cell monolayers were determined using LC-MS/MS-based quantification (triplicate experiments). After the constant infusion of each compound, the cynomolgus monkeys were sacrificed, the cerebrums were collected, and the left cerebrums were used to isolate brain microvessels using the nylon mesh method. P-gp protein expression levels in the brain microvessels of each cynomolgus monkey were determined using LC-MS/MS-based quantification (triplicate experiments for each cynomolgus monkey). Reconstructed K p brain ratios were calculated from the in-vitro P-gp efflux ratios and the P-gp protein expression levels using eq. Cynomolgus monkey plasma was spiked with 500 nM concentrations of the compounds and dialyzed against PBS (pH 7.4) at 37°C for 6 h (n = 3). One-quarter of the diluted brain homogenates of the cynomolgus monkeys was spiked with 260 nM indinavir, 559 nM quinidine, 870 nM loperamide, 3,110 nM paclitaxel, 333 nM diazepam, and 117 nM verapamil and dialyzed against ECF buffer (pH 7.4) at 37°C for 6 h to obtain the homogenate f u,brain (n = 3). The f u,brain (homogenate + pH partition model) was calculated from the homogenate f u,brain in combination with the reported pH partition model (Friden et al., 2011) using the reported pKa values of the compounds (Carvalho-Silva et al., 2004; Friden et al., 2011) . The reconstructed K p brain values were calculated from the reconstructed K p brain ratios (see Table 2 ) and the f u,plasma and f u,brain (homogenate + pH partition model) values using eq. 3.
Each value represents the mean ± S.E.M.. The S.E.M. was calculated according to the law of propagation of error. Tables 1 and 3 Tables 2 and 3 , and the mouse data were cited from Uchida et al. (2011a) .
The values of the "Impact on K p,monkey /K p,mouse " and the "Impact on K p,uu,monkey /K p,uu,mouse " describe the contributions of individual parameters to the species differences in the K p brain and K p,uu,brain values between cynomolgus monkeys and mice and were calculated using eq. 10 and 11, respectively. 
